Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

418 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Sorio R, et al. Among authors: gebski v. Gynecol Oncol. 2017 Jan;144(1):65-71. doi: 10.1016/j.ygyno.2016.11.006. Epub 2016 Nov 18. Gynecol Oncol. 2017. PMID: 27871723 Clinical Trial.
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. Pujade-Lauraine E, et al. Among authors: gebski v. J Clin Oncol. 2010 Jul 10;28(20):3323-9. doi: 10.1200/JCO.2009.25.7519. Epub 2010 May 24. J Clin Oncol. 2010. PMID: 20498395 Clinical Trial.
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Clarke SJ, Yip S, Brown C, van Hazel GA, Ransom DT, Goldstein D, Jeffrey GM, Tebbutt NC, Buck M, Lowenthal RM, Boland A, Gebski V, Zalcberg J, Simes RJ; Australasian Gastro-Intestinal Trials Group. Clarke SJ, et al. Among authors: gebski v. Eur J Cancer. 2011 Aug;47(12):1826-36. doi: 10.1016/j.ejca.2011.04.024. Epub 2011 Jun 12. Eur J Cancer. 2011. PMID: 21665462 Clinical Trial.
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M. Lee CK, et al. Among authors: gebski v. Br J Cancer. 2011 Jul 26;105(3):360-5. doi: 10.1038/bjc.2011.256. Epub 2011 Jul 12. Br J Cancer. 2011. PMID: 21750553 Free PMC article. Clinical Trial.
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.
Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, Vergote I, Pisano C, Parma G, Burges A, Bourgeois H, Högberg T, Bentley J, Angleitner-Boubenizek L, Ferrero A, Richter B, Hirte H, Gebski V, Pfisterer J, Pujade-Lauraine E, Friedlander M. Lee CK, et al. Among authors: gebski v. Br J Cancer. 2011 Oct 11;105(8):1144-50. doi: 10.1038/bjc.2011.364. Epub 2011 Sep 13. Br J Cancer. 2011. PMID: 21915127 Free PMC article.
418 results